Epistasis among Deleterious Mutations in the HIV-1 Protease

被引:23
|
作者
Parera, Mariona [1 ]
Perez-Alvarez, Nuria [2 ,3 ]
Clotet, Bonaventura [1 ,2 ]
Angel Martinez, Miguel [1 ]
机构
[1] Univ Autonoma Barcelona, Fundacio irsiCaixa, Badalona, Spain
[2] Hosp Univ Germans Trias i Pujol, Lluita SIDA Fdn, Badalona, Spain
[3] Tech Univ Catalonia, Stat & Operat Res Dept, Barcelona, Spain
关键词
epistasis; mutation; fitness; HIV-1; protease; IMMUNODEFICIENCY-VIRUS TYPE-1; GENETIC SCREEN; COMPENSATORY MUTATIONS; SYNERGISTIC EPISTASIS; CATALYTIC EFFICIENCY; FITNESS LANDSCAPE; IN-VIVO; EVOLUTION; ROBUSTNESS; RECOMBINATION;
D O I
10.1016/j.jmb.2009.07.015
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A central goal in molecular evolution is to understand how genetic interactions between protein mutations shape protein function and fitness. While intergenic epistasis has been extensively explored in eukaryotes, bacteria, and viruses, intragenic epistatic interactions have been insufficiently studied. Here, we employ a model system in which lambda phage fitness correlates with the enzymatic activity of human immunodeficiency virus type 1 (HIV-1) protease to systematically determine the epistatic interactions between intragenic pairs of deleterious protein substitutions. We generated 114 genotypes of the HIV-1 protease, each carrying pairs of nucleotide substitution mutations whose separated and combined deleterious effects on fitness were then determined. A high proportion (39%) of pairs displayed lethality. Several pairs exhibited significant interactions for fitness, including positive and negative epistasis. Significant negative epistatic interactions predominated (15%) over positive interactions (2%). However, the average +/- SD epistatic effect, (e) over bar = 0.0025 +/- 0.1334, was not significantly different from zero (p = 0.8368). Notably, epistatic interactions, regardless of epistatic direction, tend to be more frequent in the context of less deleterious mutations. In the present study, the high frequencies of lethality and negative epistasis indicate that the HIV-1 protease is highly sensitive to the effects of deleterious mutations. Therefore, proteins may not be as robust to mutational change as is usually expected. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:243 / 250
页数:8
相关论文
共 50 条
  • [21] Comment on "Evidence for positive epistasis in HIV-1''
    Wang, K
    Mittler, JE
    Samudrala, R
    SCIENCE, 2006, 312 (5775)
  • [22] Analysis of correlated mutations in HIV-1 protease using spectral clustering
    Liu, Ying
    Eyal, Eran
    Bahar, Ivet
    BIOINFORMATICS, 2008, 24 (10) : 1243 - 1250
  • [23] Molecular Determinants of Epistasis in HIV-1 Protease: Elucidating the Interdependence of L89V and L90M Mutations in Resistance
    Henes, Mina
    Kosovrasti, Klajdi
    Lockbaum, Gordon J.
    Leidner, Florian
    Nachum, Gily S.
    Nalivaika, Ellen A.
    Bolon, Daniel N. A.
    Yilmaz, Nese Kurt
    Schiffer, Celia A.
    Whitfield, Troy W.
    BIOCHEMISTRY, 2019, 58 (35) : 3711 - 3726
  • [24] Statistical analysis for linkage among HIV-1 protease sequences
    Hoffman, N
    Schiffer, C
    Swanstrom, R
    ANTIVIRAL THERAPY, 2002, 7 : S50 - S50
  • [25] Testing for epistasis between deleterious mutations in a parasitoid wasp
    Rivero, A
    Balloux, F
    West, SA
    EVOLUTION, 2003, 57 (07) : 1698 - 1703
  • [26] HIV-1 protease inhibitor
    Lloyd, AW
    DRUG DISCOVERY TODAY, 1996, 1 (06) : 261 - 261
  • [27] HIV-1 Protease Cleavages
    Abdullah, Muhammad
    Khawaja, Seher Ansar
    Farooq, Muhammad
    4TH INTERNATIONAL CONFERENCE ON INNOVATIVE COMPUTING (IC)2, 2021, : 873 - +
  • [28] INHIBITORS OF HIV-1 PROTEASE
    MEEK, TD
    JOURNAL OF ENZYME INHIBITION, 1992, 6 (01): : 65 - 98
  • [29] HIV-1 protease inhibitors
    Eron, JJ
    CLINICAL INFECTIOUS DISEASES, 2000, 30 : S160 - S170
  • [30] HIV-1 protease inhibitors
    不详
    DRUG DISCOVERY TODAY, 2001, 6 (08) : 438 - 439